The medication handling score of 82/100 also flags legitimate concerns about peptide-safe packaging
While women are included in many GLP-1 and obesity trials, enrollment proportions and subgroup reporting remain inconsistent (Rivera et al., 2024)
The most commonly reported issues appear to be similar to the gastrointestinal side effects seen with semaglutide and tirzepatide, including nausea, vomiting, constipation, and diarrhea
Lightweight Comfort: The texture of this cream is lightweight and absorbs quickly, providing a comfortable, non-greasy feel
Approximately 29%, 45%, and 51% of tirzepatide-treated participants achieved an A1C below 5.7% with the three respective doses, compared to 20% with semaglutide